- Home
- IPSC vs DHAI Comparison
IPSC vs DHAI Comparison
Compare IPSC & DHAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPSC
- DHAI
- Stock Information
- Founded
- IPSC 2019
- DHAI 2007
- Country
- IPSC United States
- DHAI United States
- Employees
- IPSC N/A
- DHAI N/A
- Industry
- IPSC Medicinal Chemicals and Botanical Products
- DHAI
- Sector
- IPSC Health Care
- DHAI
- Exchange
- IPSC Nasdaq
- DHAI NYSE
- Market Cap
- IPSC 48.2M
- DHAI 49.1M
- IPO Year
- IPSC 2021
- DHAI N/A
- Fundamental
- Price
- IPSC $0.53
- DHAI $0.23
- Analyst Decision
- IPSC Strong Buy
- DHAI
- Analyst Count
- IPSC 5
- DHAI 0
- Target Price
- IPSC $3.33
- DHAI N/A
- AVG Volume (30 Days)
- IPSC 719.1K
- DHAI 1.2M
- Earning Date
- IPSC 05-15-2025
- DHAI 07-14-2025
- Dividend Yield
- IPSC N/A
- DHAI N/A
- EPS Growth
- IPSC N/A
- DHAI N/A
- EPS
- IPSC N/A
- DHAI N/A
- Revenue
- IPSC $114,898,000.00
- DHAI $69,573,000.00
- Revenue This Year
- IPSC $833.10
- DHAI N/A
- Revenue Next Year
- IPSC N/A
- DHAI N/A
- P/E Ratio
- IPSC N/A
- DHAI N/A
- Revenue Growth
- IPSC 8286.72
- DHAI 5.40
- 52 Week Low
- IPSC $0.34
- DHAI $0.12
- 52 Week High
- IPSC $3.46
- DHAI $3.67
- Technical
- Relative Strength Index (RSI)
- IPSC 46.73
- DHAI 52.42
- Support Level
- IPSC $0.48
- DHAI $0.21
- Resistance Level
- IPSC $0.59
- DHAI $0.28
- Average True Range (ATR)
- IPSC 0.04
- DHAI 0.03
- MACD
- IPSC -0.00
- DHAI 0.01
- Stochastic Oscillator
- IPSC 34.62
- DHAI 63.15
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
About DHAI DIH HOLDINGS US INC
DIH Holding US Inc is a provider of robotic devices used in physical rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions. Its products Armeo Power, Armeo Spring, Armeo Spring Pro, etc.